More information about the Cannabinoid Product Board meetings can be found on the Utah Public Notice Website and the CPB Google Site. Search Categories: Government: State Entity: Department of Health Body: Cannabinoid Product Board.

AGENDAS MINUTES

October 27, 2020 | PDF

October 27, 2020 | PDF

October 13, 2020 | PDF

October 13, 2020 | PDF

September 22, 2020 | PDF

September 22, 2020 | PDF

August 11, 2020 | PDF

August 11, 2020 | PDF

June 9, 2020 | PDF

June 9, 2020 | PDF

April 14, 2020 | PDF

April 14, 2020 | PDF

February 11, 2020 | PDF

February 11, 2020 | PDF

January 14, 2020 | PDF

January 14, 2020 | PDF

Load More

Guidance on the Suggested Use of Medical Cannabis

2020 Annual Report

2019 Annual Report

Load More

Load More

If you would like to receive meeting reminders via email or share research or studies for CPB reference, please email medicalcannabis@utah.gov; please include  “Cannabinoid Product Board” in the subject line.


The Cannabinoid Product Board (CPB) is the result of the Cannabinoid Research Act, (H.B. 130) that was passed and was signed into law during the 2017 Utah General Legislative Session. During the 2018 Utah General Legislative Session, amendments (H.B. 25) were made to Cannabinoid Research Act as follows:

  1. The composition of the CPB was modified from three board members being members of the Controlled Substance Advisory Committee to one; and
  2. The duties of the CPB were broadened to include review of research regarding “expanded cannabinoid products” which includes cannabinoid products with significant tetrahydrocannabinol (THC) content.

The Cannabinoid Research Act directs the Utah Department of Health (UDOH) to form and facilitate the CPB. As stated in the legislation, the purpose of the CPB is to review available research related to the human use of cannabinoid products. Specifically, the CPB evaluates the safety and efficacy of cannabinoid products and expanded cannabinoid products in terms of: 1) medical conditions that respond to cannabinoid products; 2) dosage amounts and their medical forms; and 3) interactions between cannabinoid products, expanded cannabinoid products, and other treatments. The CPB may only review research that has been approved by an Institutional Review Board, or approved/conducted by the federal government.

From this research, the CPB is directed to develop prescribing guidelines that may potentially be used by qualified medical providers recommending cannabinoid products to their patients. The CPB is directed to report the findings of their evaluation in writing to the Health and Human Services Interim Committee before November 1st of each year.


BOARD MEMBERS

  • Perry G. Fine, M.D. (Board Chair)

Professor of Anesthesiology, Division of Pain Medicine, School of Medicine, University of Utah

  • Michael J. Crookston, M.D., F.A.P.A., F.A.S.A.M.

Medical Director, Adult Dayspring

  • Ed Redd, M.D.

Internal Medicine Physician

Past member of the Utah State Legislature

  • Karen S. Wilcox, Ph.D.

Professor and Chair, Department of Pharmacology and Toxicology, University of Utah

Laboratory of Glial/Neuronal Interactions in Epilepsy

  • Katherine Carlson, M.D., M.S.

Addiction Psychiatrist

Medical Director, Project Reality Substance Abuse Treatment and Prevention Services

  • Lauren J. Heath, Pharm.D., M.S., B.C.A.C.P.

Assistant Professor (Clinical), Department of Pharmacotherapy, University of Utah College of Pharmacy

  • Brian Keith Zehnder, M.D.

Medical Director, Exodus Healthcare Network, PLLC,

Past member of the Utah State Legislature